A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Nicholas J. Barrows, Rafael Kroon Campos, Steven T. Powell, K. Reddisiva Prasanth, Geraldine Schott-Lerner, Ruben Soto-Acosta, Gaddiel Galarza-Munoz, Erica L. McGrath, Rheanna Urrabaz-Garza, Junling Gao, Ping Wu, Ramkumar Menon, George Saade, Ildefonso Fernandez-Salas, Shannan Rossi, Nikos Vasilakis, Andrew Routh, Shelton Bradrick, Mariano Garcia-Blanco

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis. Currently there is no approved therapy to treat Zika virus (ZIKV) infection. Barrows et al. present a screen of FDA-approved drugs for anti-ZIKV activity in a hepatoma cell line. Selected compounds from the more than 20 identified candidates were validated in human neural stem cells and primary amnion cells.

Original languageEnglish (US)
JournalCell Host and Microbe
DOIs
StateAccepted/In press - May 15 2016

Fingerprint

Pharmaceutical Preparations
Amnion
Neural Stem Cells
Daptomycin
Mycophenolic Acid
Cell Line
Zika Virus Infection
Antiviral Agents
Hepatocellular Carcinoma
Vaccines
Zika Virus
Therapeutics
Infection

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Cancer Research
  • Molecular Biology

Cite this

A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. / Barrows, Nicholas J.; Kroon Campos, Rafael; Powell, Steven T.; Prasanth, K. Reddisiva; Schott-Lerner, Geraldine; Soto-Acosta, Ruben; Galarza-Munoz, Gaddiel; McGrath, Erica L.; Urrabaz-Garza, Rheanna; Gao, Junling; Wu, Ping; Menon, Ramkumar; Saade, George; Fernandez-Salas, Ildefonso; Rossi, Shannan; Vasilakis, Nikos; Routh, Andrew; Bradrick, Shelton; Garcia-Blanco, Mariano.

In: Cell Host and Microbe, 15.05.2016.

Research output: Contribution to journalArticle

Barrows, NJ, Kroon Campos, R, Powell, ST, Prasanth, KR, Schott-Lerner, G, Soto-Acosta, R, Galarza-Munoz, G, McGrath, EL, Urrabaz-Garza, R, Gao, J, Wu, P, Menon, R, Saade, G, Fernandez-Salas, I, Rossi, S, Vasilakis, N, Routh, A, Bradrick, S & Garcia-Blanco, M 2016, 'A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection', Cell Host and Microbe. https://doi.org/10.1016/j.chom.2016.07.004
Barrows, Nicholas J. ; Kroon Campos, Rafael ; Powell, Steven T. ; Prasanth, K. Reddisiva ; Schott-Lerner, Geraldine ; Soto-Acosta, Ruben ; Galarza-Munoz, Gaddiel ; McGrath, Erica L. ; Urrabaz-Garza, Rheanna ; Gao, Junling ; Wu, Ping ; Menon, Ramkumar ; Saade, George ; Fernandez-Salas, Ildefonso ; Rossi, Shannan ; Vasilakis, Nikos ; Routh, Andrew ; Bradrick, Shelton ; Garcia-Blanco, Mariano. / A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. In: Cell Host and Microbe. 2016.
@article{161b32ca48514ffea5e3b6cf27f2b880,
title = "A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection",
abstract = "Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis. Currently there is no approved therapy to treat Zika virus (ZIKV) infection. Barrows et al. present a screen of FDA-approved drugs for anti-ZIKV activity in a hepatoma cell line. Selected compounds from the more than 20 identified candidates were validated in human neural stem cells and primary amnion cells.",
author = "Barrows, {Nicholas J.} and {Kroon Campos}, Rafael and Powell, {Steven T.} and Prasanth, {K. Reddisiva} and Geraldine Schott-Lerner and Ruben Soto-Acosta and Gaddiel Galarza-Munoz and McGrath, {Erica L.} and Rheanna Urrabaz-Garza and Junling Gao and Ping Wu and Ramkumar Menon and George Saade and Ildefonso Fernandez-Salas and Shannan Rossi and Nikos Vasilakis and Andrew Routh and Shelton Bradrick and Mariano Garcia-Blanco",
year = "2016",
month = "5",
day = "15",
doi = "10.1016/j.chom.2016.07.004",
language = "English (US)",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",

}

TY - JOUR

T1 - A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

AU - Barrows, Nicholas J.

AU - Kroon Campos, Rafael

AU - Powell, Steven T.

AU - Prasanth, K. Reddisiva

AU - Schott-Lerner, Geraldine

AU - Soto-Acosta, Ruben

AU - Galarza-Munoz, Gaddiel

AU - McGrath, Erica L.

AU - Urrabaz-Garza, Rheanna

AU - Gao, Junling

AU - Wu, Ping

AU - Menon, Ramkumar

AU - Saade, George

AU - Fernandez-Salas, Ildefonso

AU - Rossi, Shannan

AU - Vasilakis, Nikos

AU - Routh, Andrew

AU - Bradrick, Shelton

AU - Garcia-Blanco, Mariano

PY - 2016/5/15

Y1 - 2016/5/15

N2 - Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis. Currently there is no approved therapy to treat Zika virus (ZIKV) infection. Barrows et al. present a screen of FDA-approved drugs for anti-ZIKV activity in a hepatoma cell line. Selected compounds from the more than 20 identified candidates were validated in human neural stem cells and primary amnion cells.

AB - Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis. Currently there is no approved therapy to treat Zika virus (ZIKV) infection. Barrows et al. present a screen of FDA-approved drugs for anti-ZIKV activity in a hepatoma cell line. Selected compounds from the more than 20 identified candidates were validated in human neural stem cells and primary amnion cells.

UR - http://www.scopus.com/inward/record.url?scp=84979738780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979738780&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2016.07.004

DO - 10.1016/j.chom.2016.07.004

M3 - Article

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

ER -